Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

著者: Katherine R Tuttle, Mark Lakshmanan, Brian Rayner, Robert S. Busch, Alan G. Zimmermann, D. Bradley Woodward, Fady T. Botros - The Lancet 2018 被引用: 635